Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Context Therapeutics (CNTX)

March 24, 2026 6:39 AM EDT Send to a Friend
H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $5.00 price target on Context Therapeutics (NASDAQ: CNTX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login